Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting
Efficacy of Leflunomide for Treatment of Vasculitis
Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…Abstract Number: 970 • 2019 ACR/ARP Annual Meeting
New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction
Background/Purpose: ANCA-associated vasculitis (AAV) is characterized by the production of auto-antibodies and can be treated with rituximab, a B cell-depleting agent. Despite this, limited data…Abstract Number: 1955 • 2019 ACR/ARP Annual Meeting
Association of TERT and DSP Polymorphisms with Susceptibility to Myeloperoxidase-ANCA-Associated Vasculitis
Background/Purpose: Epidemiology of ANCA-associated vasculitis (AAV) is substantially different between East Asian and European populations. Microscopic polyangiitis (MPA) and MPO-ANCA positive AAV (MPO-AAV) are prevalent…Abstract Number: 1661 • 2019 ACR/ARP Annual Meeting
Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: Fragmented cell-free DNA (cfDNA) is released into blood circulation as results of damage or death of peripheral blood cells as well as organ tissues,…Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…Abstract Number: 1662 • 2019 ACR/ARP Annual Meeting
Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Only a third of EGPA…Abstract Number: 2625 • 2019 ACR/ARP Annual Meeting
Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement
Background/Purpose: The aim of this study was to evaluate the predictors of advanced chronic kidney disease (ACKD) in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis…Abstract Number: 1664 • 2019 ACR/ARP Annual Meeting
Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial
Background/Purpose: Rituximab (RTX) superiority over azathioprine to maintain ANCA-associated vasculitis (AAV) remission was demonstrated.The MAINRITSAN2 trial was designed to compare an individually tailored RTX-infusion schedule…Abstract Number: 2627 • 2019 ACR/ARP Annual Meeting
Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis
Background/Purpose: Chronic inflammatory diseases such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) substantially affects patients’ daily lives, including their ability to work. Although the management…Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…Abstract Number: 2628 • 2019 ACR/ARP Annual Meeting
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Background/Purpose: Mortality of patients with ANCA-associated vasculitis (AAV) is higher than the general population. There are few papers in the literature regarding the factors associated…Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…Abstract Number: 2629 • 2019 ACR/ARP Annual Meeting
Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Background/Purpose: The anti-neutrophil cytoplasmic autoantibody (ANCA)- associated vasculitides (AAVs) include microscopic polyangiitis (MPA), granulomatosis with polyangitis (GPA), and eosinophilic granulomatosis with polyangitis (EGPA). These small-vessel…Abstract Number: 1669 • 2019 ACR/ARP Annual Meeting
Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis
Background/Purpose: Mizoribine (MZR) is an immunosuppressant working as an inhibitor of purine synthesis, which mechanism of action is similar to mycophenolate mofetil. MZR is approved…Abstract Number: 2630 • 2019 ACR/ARP Annual Meeting
A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis
Background/Purpose: Several guidelines have been published on the diagnosis and treatment of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV). These guidelines provide an evidence-based approach…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 20
- Next Page »